Literature DB >> 34196962

Patients, caregivers, and clinicians differ in performance status ratings: Implications for pediatric cancer clinical trials.

Scott H Maurer1, Pamela S Hinds2, Bryce B Reeve3, Jennifer W Mack4, Molly McFatrich3, Li Lin3, Janice S Withycombe5, Shana S Jacobs2, Justin N Baker6, Sharon M Castellino7, David R Freyer8,9.   

Abstract

BACKGROUND: The Lansky Play-Performance Scale (LPPS) is often used to determine a child's performance status for cancer clinical trial eligibility. Differences between clinician and caregiver LPPS ratings and their associations with child-reported functioning have not been evaluated.
METHODS: Children aged 7 to 18 years who were receiving cancer treatment and their caregivers were recruited from 9 pediatric cancer centers. Caregivers and clinicians reported LPPS scores, and children completed Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric functioning and symptom measures before treatment (time 1 [T1]) and after treatment (time 2 [T2]). t tests and mixed-linear models were used to assess differences in caregiver and clinician LPPS scores; polyserial correlations quantified associations between PROMIS and LPPS scores.
RESULTS: Of 482 children, 281 had matched caregiver- and clinician-reported LPPS T1/T2 scores. Caregivers rated children significantly worse on the LPPS than clinicians at both T1 (mean, 73.3 vs 87.4; P < .01) and T2 (mean, 67.9 vs 83.1; P < .01). These differences were not related to a child's age (P = .89), diagnosis (P = .17), or sex (P = .64) or to the time point (P = .45). Small to moderate associations existed between caregiver- and clinician-reported LPPS ratings and child-reported PROMIS scores for mobility (caregiver T1/T2 r = 0.51/0.45; P < .01; clinician T1/T2 r = 0.40/0.35; P < .01), fatigue (caregiver T1/T2 r = -0.46/-0.37; P < .01; clinician T1/T2 r = -0.26/-0.27; P < .01), and pain interference (caregiver T1/T2 r = -0.32/-0.30; P < .01; clinician T1/T2 r = -0.17/-0.31; P < .01). Caregivers and clinicians assigned significantly lower LPPS scores at T2 (caregiver Δ = -5.37; P < .01; clinician Δ = -4.20; P < .01), whereas child-reported PROMIS scores were clinically stable.
CONCLUSIONS: Significant differences between clinician and caregiver LPPS ratings of child performance were sustained over time; their associations with child reports were predominantly small to moderate. These data suggest that clinician-reported LPPS ratings by themselves are inadequate for determining clinical trial eligibility and should be supplemented by appropriate measures of a child's functional status reflecting the child and caregiver perspectives.
© 2021 American Cancer Society.

Entities:  

Keywords:  Lansky Play-Performance Scale; clinical trials; eligibility; patient-reported outcomes; pediatric oncology

Mesh:

Year:  2021        PMID: 34196962      PMCID: PMC8419065          DOI: 10.1002/cncr.33740

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.921


  25 in total

1.  Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

Authors:  Jason Fangusaro; Arzu Onar-Thomas; Tina Young Poussaint; Shengjie Wu; Azra H Ligon; Neal Lindeman; Anuradha Banerjee; Roger J Packer; Lindsay B Kilburn; Stewart Goldman; Ian F Pollack; Ibrahim Qaddoumi; Regina I Jakacki; Paul G Fisher; Girish Dhall; Patricia Baxter; Susan G Kreissman; Clinton F Stewart; David T W Jones; Stefan M Pfister; Gilbert Vezina; Jessica S Stern; Ashok Panigrahy; Zoltan Patay; Benita Tamrazi; Jeremy Y Jones; Sofia S Haque; David S Enterline; Soonmee Cha; Michael J Fisher; Laurence Austin Doyle; Malcolm Smith; Ira J Dunkel; Maryam Fouladi
Journal:  Lancet Oncol       Date:  2019-05-28       Impact factor: 41.316

2.  An item response analysis of the pediatric PROMIS anxiety and depressive symptoms scales.

Authors:  Debra E Irwin; Brian Stucky; Michelle M Langer; David Thissen; Esi Morgan Dewitt; Jin-Shei Lai; James W Varni; Karin Yeatts; Darren A DeWalt
Journal:  Qual Life Res       Date:  2010-03-07       Impact factor: 4.147

3.  Karnofsky performance status revisited: reliability, validity, and guidelines.

Authors:  C C Schag; R L Heinrich; P A Ganz
Journal:  J Clin Oncol       Date:  1984-03       Impact factor: 44.544

4.  Construction of the eight-item patient-reported outcomes measurement information system pediatric physical function scales: built using item response theory.

Authors:  Esi Morgan DeWitt; Brian D Stucky; David Thissen; Debra E Irwin; Michelle Langer; James W Varni; Jin-Shei Lai; Karin B Yeatts; Darren A Dewalt
Journal:  J Clin Epidemiol       Date:  2011-02-02       Impact factor: 6.437

5.  Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.

Authors:  Birgit Geoerger; Hyoung Jin Kang; Michal Yalon-Oren; Lynley V Marshall; Catherine Vezina; Alberto Pappo; Theodore W Laetsch; Antonio S Petrilli; Martin Ebinger; Jacek Toporski; Julia Glade-Bender; Wayne Nicholls; Elizabeth Fox; Steven G DuBois; Margaret E Macy; Susan L Cohn; Kumudu Pathiraja; Scott J Diede; Scot Ebbinghaus; Navin Pinto
Journal:  Lancet Oncol       Date:  2019-12-04       Impact factor: 41.316

6.  Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method.

Authors:  David Thissen; Yang Liu; Brooke Magnus; Hally Quinn; Debbie S Gipson; Carlton Dampier; I-Chan Huang; Pamela S Hinds; David T Selewski; Bryce B Reeve; Heather E Gross; Darren A DeWalt
Journal:  Qual Life Res       Date:  2015-06-29       Impact factor: 4.147

7.  Parental distress 6 months after a pediatric cancer diagnosis in relation to family psychosocial risk at diagnosis.

Authors:  Sasja A Schepers; Simone M Sint Nicolaas; Heleen Maurice-Stam; Lotte Haverman; Chris M Verhaak; Martha A Grootenhuis
Journal:  Cancer       Date:  2017-09-13       Impact factor: 6.860

8.  Symptom profiles in children with advanced cancer: Patient, family caregiver, and oncologist ratings.

Authors:  Donna S Zhukovsky; Cathy L Rozmus; Rhonda S Robert; Eduardo Bruera; Robert J Wells; Gary B Chisholm; Julio A Allo; Marlene Z Cohen
Journal:  Cancer       Date:  2015-07-28       Impact factor: 6.860

9.  Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.

Authors:  Giles W Robinson; Vasilisa A Rudneva; Ivo Buchhalter; Catherine A Billups; Sebastian M Waszak; Kyle S Smith; Daniel C Bowers; Anne Bendel; Paul G Fisher; Sonia Partap; John R Crawford; Tim Hassall; Daniel J Indelicato; Frederick Boop; Paul Klimo; Noah D Sabin; Zoltan Patay; Thomas E Merchant; Clinton F Stewart; Brent A Orr; Jan O Korbel; David T W Jones; Tanvi Sharma; Peter Lichter; Marcel Kool; Andrey Korshunov; Stefan M Pfister; Richard J Gilbertson; Robert P Sanders; Arzu Onar-Thomas; David W Ellison; Amar Gajjar; Paul A Northcott
Journal:  Lancet Oncol       Date:  2018-05-16       Impact factor: 41.316

10.  Expanding construct validity of established and new PROMIS Pediatric measures for children and adolescents receiving cancer treatment.

Authors:  Bryce B Reeve; Molly McFatrich; Jennifer W Mack; Laura C Pinheiro; Shana S Jacobs; Justin N Baker; Janice S Withycombe; Li Lin; Courtney M Mann; Katie R Villabroza; Pamela S Hinds
Journal:  Pediatr Blood Cancer       Date:  2020-01-06       Impact factor: 3.167

View more
  6 in total

Review 1.  The Symptom Experience in Pediatric Cancer: Current Conceptualizations and Future Directions.

Authors:  Lindsay A Jibb; Suzanne Ameringer; Catherine Fiona Macpherson; Surabhi Sivaratnam
Journal:  Curr Oncol Rep       Date:  2022-02-12       Impact factor: 5.075

2.  Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials.

Authors:  David R Freyer; Li Lin; Jennifer W Mack; Scott H Maurer; Molly McFatrich; Justin N Baker; Shana S Jacobs; Nicole Lucas; Janice S Withycombe; Deborah Tomlinson; Katie Rose Villabroza; Mia K Waldron; Pamela S Hinds; Bryce B Reeve
Journal:  J Clin Oncol       Date:  2022-03-16       Impact factor: 50.717

3.  Self-Reported Health Outcomes of Children and Youth with 10 Chronic Diseases.

Authors:  Christopher B Forrest; Julia Schuchard; Cortney Bruno; Sandra Amaral; Elizabeth D Cox; Kathryn E Flynn; Pamela S Hinds; I-Chan Huang; Michael D Kappelman; Jerry A Krishnan; Rajesh B Kumar; Jin-Shei Lai; Amy S Paller; Wanda Phipatanakul; Laura E Schanberg; Kaharu Sumino; Elissa R Weitzman; Bryce B Reeve
Journal:  J Pediatr       Date:  2022-03-02       Impact factor: 6.314

4.  Can Steps per Day Reflect Symptoms in Children and Adolescents Undergoing Cancer Treatment?

Authors:  Janice S Withycombe; Molly McFatrich; Pamela S Hinds; Antonia Bennett; Li Lin; Scott H Maurer; Nicole R Lucas; Courtney M Mann; Sharon M Castellino; Justin N Baker; Bryce B Reeve
Journal:  Cancer Nurs       Date:  2022-02-05       Impact factor: 2.760

5.  Profile Comparison of Patient-Reported and Proxy-Reported Symptoms in Pediatric Patients With Cancer Receiving Chemotherapy.

Authors:  Meaghann S Weaver; Shana S Jacobs; Janice S Withycombe; Jichuan Wang; Katie A Greenzang; Justin N Baker; Pamela S Hinds
Journal:  JAMA Netw Open       Date:  2022-03-01

6.  Large Improvements in Health-Related Quality of Life and Physical Fitness during Multidisciplinary Inpatient Rehabilitation for Pediatric Cancer Survivors.

Authors:  David Riedl; Thomas Licht; Alain Nickels; Maria Rothmund; Gerhard Rumpold; Bernhard Holzner; Vincent Grote; Michael J Fischer; Gustav Fischmeister
Journal:  Cancers (Basel)       Date:  2022-10-04       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.